Attached files
file | filename |
---|---|
EX-99.1 - ADDITIONAL EXHIBITS - AzurRx BioPharma, Inc. | ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of
1934
Date of
Report (Date of Earliest Event Reported): March 1,
2017
AzurRx BioPharma, Inc.
(Exact
name of registrant as specified in its charter)
Delaware
State
or other jurisdiction of incorporation
001-37853
|
46-4993860
|
(Commission File
Number)
|
(IRS Employer
Identification No.)
|
760 Parkside Avenue
Downstate Biotechnology Incubator, Suite 217
Brooklyn,
New York 11226
(Address
of principal executive offices and zip code)
(646)
699-7855
(Registrant's
telephone number including area code)
(Registrant's
former name or former address, if changed since last
report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of registrant under
any of the following provisions:
[ ]
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
[ ]
Soliciting material pursuant to Rule 14a-12(b) under the Exchange
Act (17 CFR 240.14a-12(b))
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
On
March 1, 2017, AzurRx BioPharma, Inc. (the "Company") began using the
corporate presentation materials attached hereto as Exhibit 99.1,
which presentation is posted on the Company’s website located
at www.azurrx.com.
The Company may continue to use these materials from time to time
in conversations with investors and analysts.
Item 9.01 Financial Statements and Exhibits
See
Exhibit Index.
Disclaimer
In
accordance with General Instruction B.2 of Form 8-K, the
information contained in Item 7.01 of this Current Report on Form
8-K, including Exhibit 99.1 attached hereto, shall not be deemed
"filed" for the purposes of Section 18 of the Securities Exchange
Act of 1934, as amended, or otherwise subject to the liabilities of
that Section. The information in Item 7.01 of this Current Report
on Form 8-K shall not be incorporated by reference into any filing
or other document pursuant to the Securities Act of 1933, as
amended, except as shall be expressly set forth by specific
reference in such filing or document.
Exhibit
No.
|
|
Description
|
|
|
|
99.1
|
|
Corporate
Presentation
|
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the Registrant
has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
|
AZURRX BIOPHARMA,
INC.
By:
/s/ Johan M. (Thijs)
Spoor
Name:
Johan M. (Thijs) Spoor
Title:
President and CEO
|
Dated:
March 1, 2017